AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12225508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 5
Study 12225508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 5
Study 12225508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9648550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (low-dose D2 dopamine receptor agonist)
Number of subjects: 24
Study 7988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2 on days 1 and 29) and fluorouracil (1 g/m2 for 24 h as continuous infusion on days 1 to 4 and 29 to 32) with thoracic radiation (30 Gy in 15 fractions on days 1 to 19)
Number of subjects: 85
Study 7988261 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 85
Study 2567439 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at points specific for the treatment of substance abuse
Number of subjects: 80
Study 2567439 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at nonspecific points (control group)
Number of subjects: 80
Study 4396186 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 4396186 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 12
Study 4396186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4396186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 12
Study 31762434 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori-based activities
Number of subjects: 40
Study 31762434 — intervention group
Group type: COMPARATOR
Intervention: Reading a newspaper (control condition)
Number of subjects: 40
Study 30921645 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan hydrochloride liposome injection (IHLI)
Number of subjects: 0
Study 28679449 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 3 mg/kg on day 1, 15, and 29, followed by 10 mg/kg every 28 days for 5 months
Number of subjects: 15
Study 28679449 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg
Number of subjects: 15
Study 28679449 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 15
Study 28679449 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study 26596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib alone 40 mg orally once per day
Number of subjects: 121
Study 26596672 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine 40 mg per day plus intravenous vinorelbine 25 mg/m2 once per week
Number of subjects: 121
Study 26596672 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice
Number of subjects: 121
Study 23808999 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine hydrochloride (500 mg) three times daily before meals for 3 months
Number of subjects: 24
Study 22189642 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute Maid Original® (MM)
Number of subjects: 80
Study 22189642 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic Juice (SJ)
Number of subjects: 80
Study 22189642 — intervention group
Group type: COMPARATOR
Intervention: 1% Citric Acid (CA)
Number of subjects: 80
Study 22189642 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Natural Original® (FN)
Number of subjects: 80
Study 19501755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating with a friend
Number of subjects: 57
Study 19501755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing from a common serving bowl
Number of subjects: 57
Study 19501755 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating from small plates
Number of subjects: 57
Study 19501755 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking second helpings
Number of subjects: 57
Study 17132050 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI brain responses to novel sequences of objects during an incidental target detection task
Number of subjects: 0
Study 17132050 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI brain responses to novel sequences of objects
Number of subjects: 0
Study 12860548 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxin
Number of subjects: 5
Study 12860548 — intervention group
Group type: COMPARATOR
Intervention: Control (Men)
Number of subjects: 5
Study 10854946 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMP (vindesine, cisplatin, bleomycin, mitomycin-C)
Number of subjects: 4424
Study 9104380 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information video during the informed consent process
Number of subjects: 90
Study 9104380 — intervention group
Group type: COMPARATOR
Intervention: Written information only
Number of subjects: 90
Study 8256085 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study 8256085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3510617 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 10
Study 3510617 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine maleate
Number of subjects: 10
Study 3510617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29180454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (8 weeks treatment)
Number of subjects: 0
Study 29180454 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (active control)
Number of subjects: 0
Study 27744584 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (INT) training (3-5 RM, 3-min rest interval)
Number of subjects: 29
Study 27744584 — intervention group
Group type: COMPARATOR
Intervention: High volume (VOL) training (10-12 RM, 1-min rest interval)
Number of subjects: 29
Study 27744584 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity (INT) training
Number of subjects: 29
Study 27744584 — intervention group
Group type: COMPARATOR
Intervention: High volume (VOL) training
Number of subjects: 29
Study 27744584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both INT and VOL training
Number of subjects: 29
Study 24888475 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation scenario with additional distractors (noise, scripted family member)
Number of subjects: 30
Study 24888475 — intervention group
Group type: COMPARATOR
Intervention: Control scenario without additional distractors
Number of subjects: 30
Study 22437999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrepid Dynamic Exoskeletal Orthosis (IDEO)
Number of subjects: 18
Study 22437999 — intervention group
Group type: COMPARATOR
Intervention: BlueRocker
Number of subjects: 18
Study 22437999 — intervention group
Group type: COMPARATOR
Intervention: Posterior leaf spring orthosis
Number of subjects: 18
Study 22437999 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 18
Study 19712933 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD+VOO
Number of subjects: 49
Study 19712933 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD+nuts
Number of subjects: 49
Study 19712933 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 49
Study 17938573 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208S (10(9) CFU)
Number of subjects: 16
Study 17938573 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 1208S (10(8) CFU)
Number of subjects: 16
Study 17938573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15723448 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg every 12 hours for a total of 5 doses)
Number of subjects: 28
Study 15723448 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg every 12 hours for a total of 5 doses)
Number of subjects: 28
Study 15723448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12422093 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical thrombectomy
Number of subjects: 0
Study 12422093 — intervention group
Group type: COMPARATOR
Intervention: Endovascular procedures
Number of subjects: 0
Study 9613786 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional inpatient setting
Number of subjects: 94
Study 9613786 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial outpatient setting
Number of subjects: 94
Study 9613786 — intervention group
Group type: EXPERIMENTAL
Intervention: Total outpatient setting
Number of subjects: 94
Study 9613786 — intervention group
Group type: COMPARATOR
Intervention: All settings combined
Number of subjects: 94
Study 7625622 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol twice daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol three times daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol four times daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol twice daily vs. Misoprostol three times daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol four times daily
Number of subjects: 1197
Study 7625622 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol twice daily and three times daily
Number of subjects: 1197
Study 2196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 74
Study 2196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 74
Study 2196620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 343500 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 34
Study 343500 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nitrazepam
Number of subjects: 34
Study 31812487 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (n = 32)
Number of subjects: 69
Study 31812487 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 69
Study 31196447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 165502
Study 31196447 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 165502
Study 26342731 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression (ECI)
Number of subjects: 1084
Study 26342731 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 1084
Study 23656257 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support amount among caregivers
Number of subjects: 188
Study 23656257 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping methods among caregivers
Number of subjects: 188
Study 23656257 — intervention group
Group type: COMPARATOR
Intervention: Social support satisfaction
Number of subjects: 188
Study 23656257 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support by health status
Number of subjects: 188
Study 21098507 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate therapy
Number of subjects: 0
Study 19212615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial infusion (TAI) of 120 mg/body cisplatin twice a month at an interval of 4 weeks
Number of subjects: 26
Study 15999305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvitrainer (PT)
Number of subjects: 12
Study 15999305 — intervention group
Group type: COMPARATOR
Intervention: Rabbit model (RM)
Number of subjects: 12
Study 12439700 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m²) before HDM (200 mg/m²)
Number of subjects: 41
Study 10734533 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and self breast examination
Number of subjects: 3003
Study 10734533 — intervention group
Group type: COMPARATOR
Intervention: Baseline study
Number of subjects: 3003
Study 1776746 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids (EFAs) plus appropriate antioxidants
Number of subjects: 36
Study 1776746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7347596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine of sustained release
Number of subjects: 20
Study 7347596 — intervention group
Group type: COMPARATOR
Intervention: Conventional cimetidine
Number of subjects: 20
Study 31577036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen with noninvasive ventilation (NIV)
Number of subjects: 641
Study 31577036 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal oxygen alone
Number of subjects: 641
Study 29104871 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 20
Study 29104871 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 20
Study 29104871 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI > 25 kg/m2)
Number of subjects: 20
Study 29104871 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 20
Study 25180558 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated EEG biofeedback (AEB)
Number of subjects: 95
Study 25180558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician guided EEG biofeedback (CEB)
Number of subjects: 95
Study 25180558 — intervention group
Group type: COMPARATOR
Intervention: Additional therapy sessions (AT)
Number of subjects: 95
Study 23809621 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 23809621 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 21136031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy for 3 months
Number of subjects: 43
Study 21136031 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment only)
Number of subjects: 43
Study 19916293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (thick-needle subcutaneous penetration of Shendao (GV 11), retained for 4 h/time, once daily, 5 times/week)
Number of subjects: 60
Study 19916293 — intervention group
Group type: COMPARATOR
Intervention: Medication (Levocetirizine Hydrochloride tablets, 5 mg/time, once daily for first two weeks, then once every other day in the 3rd and 4th weeks, and once every 3 days in the last two weeks)
Number of subjects: 60
Study 19916293 — intervention group
Group type: COMPARATOR
Intervention: Comparison between acupuncture and medication groups
Number of subjects: 60
Study 17502627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin alone
Number of subjects: 526
Study 17502627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 526
Study 17502627 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 526
Study 15182272 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg/puff, 12 puffs daily
Number of subjects: 0
Study 15182272 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 20 microg/puff, 12 puffs daily
Number of subjects: 0
Study 12362966 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI) session
Number of subjects: 126
Study 12362966 — intervention group
Group type: EXPERIMENTAL
Intervention: Role Induction (RI) session
Number of subjects: 126
Study 12362966 — intervention group
Group type: COMPARATOR
Intervention: No-preparatory session (Control Group - CG)
Number of subjects: 126
Study 9660095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 18
Study 9660095 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg melatonin
Number of subjects: 18
Study 9660095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9660095 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II (4, 8 and 16 ng/kg/min)
Number of subjects: 18
Study 8018001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5 mg/d and Hydrochlorothiazide 6.25 mg/d
Number of subjects: 512
Study 8018001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 6.25 mg/d
Number of subjects: 512
Study 8018001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol and Hydrochlorothiazide (various combinations)
Number of subjects: 512
Study 8018001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 2642455 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + BCG (DC + BCG)
Number of subjects: 185
Study 2642455 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + cisplatin (DCP)
Number of subjects: 185
Study 2642455 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin + cyclophosphamide + cisplatin + BCG (DCP + BCG)
Number of subjects: 185
Study 789844 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (100 mug three times daily)
Number of subjects: 0
Study 29543570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational suicide vignette
Number of subjects: 117
Study 29543570 — intervention group
Group type: COMPARATOR
Intervention: Nonrational suicide vignette
Number of subjects: 117
Study 29543570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rational and Nonrational)
Number of subjects: 117
Study 28350640 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG) supplementation
Number of subjects: 32
Study 28350640 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise
Number of subjects: 32
Study 25314034 — intervention group
Group type: EXPERIMENTAL
Intervention: RME on second deciduous molars (GrE)
Number of subjects: 70
Study 25314034 — intervention group
Group type: COMPARATOR
Intervention: RME on first permanent molars (Gr6)
Number of subjects: 70
Study 23586594 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management interactive support (SMIS) program
Number of subjects: 65
Study 23586594 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 65
Study 21877102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskinetic PD subjects off L-dopa
Number of subjects: 29
Study 21877102 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dyskinetic PD subjects off L-dopa
Number of subjects: 29
Study 21877102 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 29
Study 18644069 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat
Number of subjects: 504
Study 18644069 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 504
Study 17191415 — intervention group
Group type: EXPERIMENTAL
Intervention: Araoye's criteria
Number of subjects: 100
Study 17191415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sokolow‐Lyon criteria
Number of subjects: 100
Study 17191415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornell's criteria
Number of subjects: 100
Study 17191415 — intervention group
Group type: EXPERIMENTAL
Intervention: Romhilt‐Estes score
Number of subjects: 100
Study 17191415 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic LVH
Number of subjects: 100
Study 12551858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx Velocity stenting (slow release)
Number of subjects: 30
Study 12551858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting Bx Velocity stenting (fast release)
Number of subjects: 30
Study 12551858 — intervention group
Group type: COMPARATOR
Intervention: Entire cohort
Number of subjects: 30
Study 8550745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate infusion
Number of subjects: 11
Study 8550745 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion (sodium chloride)
Number of subjects: 11
Study 1646724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3.0 g) with 5 mg glipizide
Number of subjects: 0
Study 1646724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium hydroxide (1.0 g) with 5 mg glipizide
Number of subjects: 0
Study 1646724 — intervention group
Group type: COMPARATOR
Intervention: Control (150 ml water with 5 mg glipizide)
Number of subjects: 0
Study 6312664 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opiate/opioid antagonist)
Number of subjects: 28
Study 6312664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31925414 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence reminder and symptom management intervention using the Symptom Management Toolkit during eight automated telephone weekly calls.
Number of subjects: 127
Study 31277181 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated directed-learning in a life-education intervention
Number of subjects: 54
Study 29073928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal ligation by minilaparotomy provided by clinical officers (COs)
Number of subjects: 1970
Study 29073928 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation by minilaparotomy provided by assistant medical officers (AMOs)
Number of subjects: 1970
Study 25105284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary disease management programme (MDP)
Number of subjects: 349
Study 24820145 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg/day for 3 months
Number of subjects: 90
Study 21927938 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpexin Sphere plus pelvic floor muscle exercise
Number of subjects: 91
Study 21927938 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 91
Study 19567688 — intervention group
Group type: EXPERIMENTAL
Intervention: Active offer of prenatal screening test
Number of subjects: 59
Study 19567688 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion opportunity with caregivers
Number of subjects: 59
Study 17499292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine gel instillation before periprostatic neurovascular bundle block
Number of subjects: 250
Study 17499292 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic neurovascular bundle block without lidocaine gel instillation
Number of subjects: 250
Study 15350440 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) at a dose of 1.44 g/d (0.450 g/m² bid for children)
Number of subjects: 93
Study 15350440 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 93